Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Levodopa. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.52 |
| ▸ | SLC7A5 | Q01650 | 6/20 | 0.96 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.96 |
| ▸ | ALOX15 | P16050 | 5/20 | 0.96 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.96 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.96 |
| ▸ | USP2 | O75604 | 4/20 | 0.96 |
| ▸ | RECQL | P46063 | 4/20 | 0.96 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.96 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.96 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.96 |
| ▸ | HTR2A | P28223 | 2/20 | 0.96 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.96 |
| ▸ | EGFR | P00533 | 1/20 | 0.96 |
| ▸ | LCK | P06239 | 1/20 | 0.96 |
| ▸ | FYN | P06241 | 1/20 | 0.96 |
| ▸ | KDM6B | O15054 | 1/20 | 0.64 |
| ▸ | PKM | P14618 | 3/20 | 0.56 |
| ▸ | ALPI | P09923 | 1/20 | 0.56 |
| ▸ | XIAP | P98170 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Levodopa SCHEMBL31384812 | 1.00 | SLC7A5 (0.96) | SLC7A5KDM4EALOX15HIF1AHSD17B10 | |
| Levodopa SCHEMBL29396307 | 1.00 | SLC7A5 (0.96) | SLC7A5KDM4EALOX15HIF1AHSD17B10 | |
| Levodopa SCHEMBL29242657 | 1.00 | SLC7A5 (0.96) | SLC7A5KDM4EALOX15HIF1AHSD17B10 | |
| Levodopa SCHEMBL30690154 | 1.00 | SLC7A5 (0.96) | SLC7A5KDM4EALOX15HIF1AHSD17B10 | |
| Levodopa SCHEMBL1278779 | 1.00 | SLC7A5 (0.96) | SLC7A5KDM4EALOX15HIF1AHSD17B10 | |
| Levodopa SCHEMBL31471689 | 0.98 | SLC7A5 (0.93) | SLC7A5KDM4EALOX15HIF1AHSD17B10 | |
| Levodopa SCHEMBL28333192 | 0.98 | SLC7A5 (0.93) | SLC7A5KDM4EALOX15HIF1AHSD17B10 | |
| Levodopa SCHEMBL22655 | 0.98 | SLC7A5 (1.00) | SLC7A5KDM4EALOX15HIF1AHSD17B10 | |
| Levodopa SCHEMBL20582239 | 0.98 | SLC7A5 (1.00) | SLC7A5KDM4EALOX15HIF1AHSD17B10 | |
| Levodopa SCHEMBL704089 | 0.98 | SLC7A5 (1.00) | SLC7A5KDM4EALOX15HIF1AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120464197-B | Polyimide film and preparation method and application thereof | Jiaxing Nanbo Precision Manufacturing Co.,Ltd. (CN) | 2026-05-26 | — | — | CN | claimed |
| CN-119959539-A | System for targeted quantitative detection of breast cancer cells in blood, and preparation method and application thereof | 中南大学 | 2025-05-09 | — | — | CN | claimed |
| CN-118685005-A | Cellulose acetate/PBAT biodegradable composite material and preparation method thereof | 福建技术师范学院 | 2024-09-24 | — | — | CN | claimed |
| CN-112316218-B | Zwitterionic polymer and heparin composite coating, preparation method and application thereof | 西北大学 | 2021-12-10 | — | — | CN | claimed |
| CN-112316218-A | Zwitterionic polymer and heparin composite coating, preparation method and application thereof | 西北大学 | 2021-02-05 | — | — | CN | claimed |
| CN-107441555-B | Preparation method of artificial skin capable of controllably releasing medicine | 中山大学附属第一医院 | 2020-10-30 | — | — | CN | claimed |
| CN-111171332-A | Nitric oxide releasing hydrogel and preparation method thereof | 广州贝奥吉因生物科技股份有限公司 | 2020-05-19 | — | — | CN | claimed |
| WO-2020035853-A1 | PROCESS FOR PREPARING PURIFIED LEVODOPAMIDE FREE BASE | NEURODERM, LTD. (IL) | 2020-02-20 | — | — | WO | claimed |
| WO-2019038638-A1 | PROCESS FOR PREPARING PURIFIED LEVODOPA AMIDE | NEURODERM LTD (IL) | 2019-02-28 | — | — | WO | claimed |
| US-8324272-B2 | Levodopa dimethyl-substituted diester prodrugs, compositions, and methods of use | XENOPORT, INC. (US) | 2012-12-04 | — | — | US | claimed |
| US-20100173992-A1 | LEVODOPA DIMETHYL-SUBSTITUTED DIESTER PRODRUGS, COMPOSITIONS, AND METHODS OF USE | XENOPORT, INC. (US) | 2010-07-08 | — | — | US | claimed |
| US-7709527-B2 | 2-acetyloxy-1-methylpropyl (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate; Parkinson's disease; crystalline forms; improved pharmacokinetics; oral administration | XENOPORT, INC. (US) | 2010-05-04 | — | — | US | claimed |
| EP-2125702-A1 | LEVODOPA DIMETHYL-SUBSTITUTED DIESTER PRODRUGS, COMPOSITIONS, AND METHODS OF USE | Xenoport, Inc. (US) | 2009-12-02 | — | — | EP | claimed |
| US-20090137834-A1 | LEVODOPA PRODRUGS, AND COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2009-05-28 | — | — | US | claimed |
| US-7534813-B2 | Levodopa prodrugs, and compositions and uses thereof | XENOPORT, INC. (US) | 2009-05-19 | — | — | US | claimed |
| US-20080214663-A1 | Levodopa dimethyl-substituted diester prodrugs compositions, and methods of use | XENOPORT, INC. | 2008-09-04 | — | — | US | claimed |
| WO-2008076458-A1 | LEVODOPA DIMETHYL-SUBSTITUTED DIESTER PRODRUGS, COMPOSITIONS, AND METHODS OF USE | XENOPORT, INC. (US) | 2008-06-26 | — | — | WO | claimed |
| US-7342131-B2 | Levodopa prodrugs, and compositions and uses thereof | XENOPORT, INC. (US) | 2008-03-11 | — | — | US | claimed |
| US-20050282891-A1 | Levodopa prodrugs, and compositions and uses thereof | WILSHIRE PHARMACEUTICALS, INC. | 2005-12-22 | — | — | US | claimed |
| US-5273550-A | Using 5,6-dihydroxyindole obtained from the oxidation of dopa to diffuse into the hair and generate a hair coloring amount of melanin | CLAIROL INCORPORATED (US) | 1993-12-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173992-A1 | LEVODOPA DIMETHYL-SUBSTITUTED DIESTER PRODRUGS, COMPOSITIONS, AND METHODS OF USE | COMT, DDT, DDC | DRD3 42/4885SLC7A5 975/4885KDM4E 1443/4885 |
| US-20050282891-A1 | Levodopa prodrugs, and compositions and uses thereof | COMT, DDT, DDC | DRD3 144/4885SLC7A5 468/4885KDM4E 2224/4885 |
| US-20080214663-A1 | Levodopa dimethyl-substituted diester prodrugs compositions, and methods of use | COMT, DDT, DDC | DRD3 59/4885SLC7A5 906/4885KDM4E 1558/4885 |
| US-20090137834-A1 | LEVODOPA PRODRUGS, AND COMPOSITIONS AND USES THEREOF | COMT, DDT, DDC | DRD3 144/4885SLC7A5 468/4885KDM4E 2224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.